This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /sign-in page

You can view 5 more pages before signing in

Conclusions

Authoring team

The conclusion reached from the trial was that single-agent carboplatin and CAP were as effective as paclitaxel plus carboplatin as first-line treatment for women requiring chemotherapy for ovarian cancer.

The favourable toxicity profile of single-agent carboplatin suggested that this drug is a reasonable option as first-line chemotherapy for ovarian cancer.

 

Note - the usual first line chemotherapeutic agents for epithelial ovarian cancer are currently platinum-based cisplatin or carboplatin, along with a taxane family agent, paclitaxel or docetaxel. (1)

Bevacizumab is approved in the treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with a carboplatin chemotherapy regimen or the treatment of platinum-resistant disease in combination with paclitaxel, doxorubicin, or topotecan. (2)

Reference

  1. Sambasivan S. Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 2022;33:100629
  2. Marchetti C, Muzii L, Romito A, Benedetti Panici P. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;12:1095-1103.

 

 

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.